Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug-Reference-Cited by-同舟云学术

Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug

Published:2015-10-02 Issue:10 Volume:10 Page:e0140011
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Song Xianzhou,Zhang Chengwei,Zhao Mingkun,Chen Hui,Liu Xing,Chen Jianwei,Lonard David M.,Qin Li,Xu Jianming,Wang Xiaosong,Li Feng,O’Malley Bert W.,Wang Jin

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference65 articles.

1. Triple negative breast cancer: current understanding of biology and treatment options;SP Kang;Curr Opin Obstet Gynecol,2008

2. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective;F Penault-Llorca;Ann Oncol,2012

3. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up;L Malorni;Breast Cancer Res Treat,2012

4. Pharmacogenetics of breast cancer: toward the individualization of therapy;JC Chang;Cancer Invest,2009

5. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models;A Bandyopadhyay;PLoS One,2010

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy;Journal of Medicinal Chemistry;2024-03-29

2. An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives;Frontiers in Pharmacology;2023-10-04

3. AIB1/SRC-3/NCOA3 function in estrogen receptor alpha positive breast cancer;Frontiers in Endocrinology;2023-08-30

4. Significant Association of Estrogen Receptor-β Isoforms and Coactivators in Breast Cancer Subtypes;Current Issues in Molecular Biology;2023-03-17

5. Bufalin for an innovative therapeutic approach against cancer;Pharmacological Research;2022-10